Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152375 | PMC |
| http://dx.doi.org/10.1001/jamainternmed.2023.0334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
National Survey of Lung Cancer Screening Eligibility in United States Veterans.
Am J Prev Med
January 2025
Veterans Health Administration-Tennessee Valley Healthcare System, Geriatric Research, Education and Clinical Center (GRECC) and the VETWISE-LHS Center of Innovation, Nashville, TN; Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Center for Clinical Quality and Implementation Research, Vanderbilt University Medical Center, Nashville, TN; Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN.
Introduction: Lung cancer screening is underutilized, especially in rural areas where lung cancer mortality is high. Approximately 11.2% of the United States (US) population over age 50 meet the United States Preventive Services Task Force (USPSTF) 2021 lung cancer screening eligibility criteria; the proportion of eligible Veterans is unknown.
View Article and Find Full Text PDFNext-Generation Sequencing Analysis on Image-Guided Biopsy Samples in Early-Stage Lung Cancer: Feasibility Study and Comparison With Surgical Samples.
JTO Clin Res Rep
February 2025
Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, New York.
Introduction: Limited information exists on next-generation sequencing (NGS) success for lung tumors of 30 mm or less. We aimed to compare NGS success rates across biopsy techniques for these tumors, assess DNA sequencing quality, and verify reliability against surgical resection results.
Methods: We used data from the Initiative for Early Lung Cancer Research on Treatment study, including patients with lung tumors measuring 30 mm or less who had surgery and NGS on biopsies since 2016.
Anthracyclines disaggregate and restore mutant p63 function: a potential therapeutic approach for AEC syndrome.
Cell Death Discov
January 2025
Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, 02129, USA.
Ankyloblepharon-Ectodermal Defects-Cleft Lip/Palate (AEC) syndrome is a rare genetic disorder caused by mutations in the TP63 gene, which encodes a transcription factor essential for epidermal gene expression. A key feature of AEC syndrome is chronic skin erosion, for which no effective treatment currently exists. Our previous studies demonstrated that mutations associated with AEC syndrome lead to p63 protein misfolding and aggregation, exerting a dominant-negative effect.
View Article and Find Full Text PDFEarly intervention with daratumumab improves survival for patients with high-risk smouldering myeloma.
Nat Rev Clin Oncol
January 2025
Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies.
Leukemia
January 2025
Department of Medicine; Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Article Synopsis
- This study focuses on PRT543, a new oral medication designed to inhibit PRMT5, an enzyme implicated in the growth of certain blood cancers.
- It specifically investigates the effects of PRT543 in patients suffering from advanced myeloid malignancies that have mutations in splicing factors, which are crucial for proper gene expression and can contribute to cancer progression.
- The early Phase Ib trial aims to assess the safety, tolerability, and initial effectiveness of PRT543 in these patients, providing groundwork for potential future treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!